Hai Nan Yao Gu Yun Sheng Wu Ke Ji You Xian Gong Si

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of acipimox capsule test formulation (specification: 0.25g, applicant: Hainan Yaoguyun Biotechnology Co., Ltd.) and reference formulation (trade name: Olbetam®, specification: 0.25g, licensee: Pfizer Limited) after single oral administration under fasting and postprandial conditions in healthy Chinese adult subjects. Secondary study objectives To study the safety of acipimox capsule test formulation (specification: 0.25g) and reference formulation (trade name: Olbetam®, specification: 0.25g) in healthy Chinese adult subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of candesartan cilexetil tablets (specification: each tablet contains 16 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide) owned by Hainan Yaoguyun Biotechnology Co., Ltd. and produced by Jiangsu Chengkang Pharmaceutical Co., Ltd. and candesartan cilexetil tablets (trade name: Blopress®, specification: each tablet contains 16 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide) licensed by CHEPLAPHARM Arzneimittel GmbH in healthy Chinese subjects under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test and reference preparations of candesartan cilexetil tablets taken orally at a single dose in healthy Chinese subjects.

Main study objectives This study investigated the pharmacokinetics of the test preparation clopidogrel bisulfate tablets (specification: 75 mg/tablet, manufacturer: Hangzhou Minsheng Pharmaceutical Co., Ltd.) and the reference preparation clopidogrel bisulfate tablets (trade name: Plavix®, specification: 75 mg/tablet, manufacturer: Sanofi Wint hrop Industrie) in healthy adult subjects after a single oral administration under fasting and postprandial conditions, and evaluated the bioequivalence of the two preparations after fasting and postprandial oral administration. Secondary study objectives Observe the safety of a single oral administration of 75 mg of the test preparation clopidogrel bisulfate tablets or the reference preparation clopidogrel bisulfate tablets (trade name: Plavix®, 75 mg) in healthy subjects.